miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein

被引:1
作者
Tonouchi, Erina [1 ,2 ]
Gen, Yasuyuki [1 ]
Muramatsu, Tomoki [1 ]
Hiramoto, Hidekazu [1 ]
Tanimoto, Kousuke [3 ]
Inoue, Jun [1 ]
Inazawa, Johji [1 ,4 ]
机构
[1] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan
[2] Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Tokyo, Japan
[3] TMDU, Med Res Inst, Genome Lab, Tokyo, Japan
[4] Tokyo Med & Dent Univ, Bioresource Res Ctr, Bunkyo Ku, Tokyo, Japan
关键词
BET BROMODOMAIN INHIBITORS; SELECTIVE-INHIBITION; LUNG-CANCER; PROTEINS; EGFR; ADENOCARCINOMA; RESISTANCE; MUTATIONS; CHROMATIN; MICRORNAS;
D O I
10.1038/s41598-018-22767-y
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Bromodomain Containing 4 (BRD4) mediates transcriptional elongation of the oncogene MYC by binding to acetylated histones. BRD4 has been shown to play a critical role in tumorigenesis in several cancers, and the BRD4-NUT fusion gene is a driver of NUT midline carcinoma (NMC), a rare but highly lethal cancer. microRNAs (miRNAs) are endogenous small non-coding RNAs that suppress target gene expression by binding to complementary mRNA sequences. Here, we show that miR-3140, which was identified as a novel tumor suppressive miRNA by function-based screening of a library containing 1090 miRNA mimics, directly suppressed BRD4 by binding to its coding sequence (CDS). miR-3140 concurrently downregulated BRD3 by bind to its CDS as well as CDK2 and EGFR by binding to their 3' untranslated regions. miR-3140 inhibited tumor cell growth in vitro in various cancer cell lines, including EGFR tyrosine kinase inhibitor-resistant cells. Interestingly, we found that miR-3140 downregulated the BRD4-NUT fusion protein and suppressed in vitro tumor cell growth in a NMC cell line, Ty-82 cells. Furthermore, administration of miR-3140 suppressed in vivo tumor growth in a xenograft mouse model. Our results suggest that miR-3140 is a candidate for the development of miRNA-based cancer therapeutics.
引用
收藏
页数:13
相关论文
共 56 条
[1]   miR-432 Induces NRF2 Stabilization by Directly Targeting KEAP1 [J].
Akdemir, Burak ;
Nakajima, Yasuaki ;
Inazawa, Johji ;
Inoue, Jun .
MOLECULAR CANCER RESEARCH, 2017, 15 (11) :1570-1578
[2]   Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma [J].
Alekseyenko, Artyom A. ;
Walsh, Erica M. ;
Zee, Barry M. ;
Pakozdi, Tibor ;
Hsi, Peter ;
Lemieux, Madeleine E. ;
Dal Cin, Paola ;
Ince, Tan A. ;
Kharchenko, Peter V. ;
Kuroda, Mitzi I. ;
French, Christopher A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (21) :E4184-E4192
[3]   Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study [J].
Amorim, Sandy ;
Stathis, Anastasios ;
Gleeson, Mary ;
Iyengar, Sunil ;
Magarotto, Valeria ;
Leleu, Xavier ;
Morschhauser, Franck ;
Karlin, Lionel ;
Broussais, Florence ;
Rezai, Keyvan ;
Herait, Patrice ;
Kahatt, Carmen ;
Lokiec, Francois ;
Salles, Gilles ;
Facon, Thierry ;
Palumbo, Antonio ;
Cunningham, David ;
Zucca, Emanuele ;
Thieblemont, Catherine .
LANCET HAEMATOLOGY, 2016, 3 (04) :E196-E204
[4]   The history and future of targeting cyclin-dependent kinases in cancer therapy [J].
Asghar, Uzma ;
Witkiewicz, Agnieszka K. ;
Turner, Nicholas C. ;
Knudsen, Erik S. .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :130-146
[5]   BET domain co-regulators in obesity, inflammation and cancer [J].
Belkina, Anna C. ;
Denis, Gerald V. .
NATURE REVIEWS CANCER, 2012, 12 (07) :465-477
[6]   Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study [J].
Berthon, Celine ;
Raffoux, Emmanuel ;
Thomas, Xavier ;
Vey, Norbert ;
Gomez-Roca, Carlos ;
Yee, Karen ;
Taussig, David Christopher ;
Rezai, Keyvan ;
Roumier, Christophe ;
Herait, Patrice ;
Kahatt, Carmen ;
Quesnel, Bruno ;
Michallet, Mauricette ;
Recher, Christian ;
Lokiec, Francois ;
Preudhomme, Claude ;
Dombret, Herve .
LANCET HAEMATOLOGY, 2016, 3 (04) :E186-E195
[7]   Short Hairpin RNA Screen Reveals Bromodomain Proteins as Novel Targets in Acute Myeloid Leukemia [J].
Blobel, Gerd A. ;
Kalota, Anna ;
Sanchez, Patricia V. ;
Carroll, Martin .
CANCER CELL, 2011, 20 (03) :287-288
[8]   Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma [J].
Chapuy, Bjoern ;
McKeown, Michael R. ;
Lin, Charles Y. ;
Monti, Stefano ;
Roemer, Margaretha G. M. ;
Qi, Jun ;
Rahl, Peter B. ;
Sun, Heather H. ;
Yeda, Kelly T. ;
Doench, John G. ;
Reichert, Elaine ;
Kung, Andrew L. ;
Rodig, Scott J. ;
Young, Richard A. ;
Shipp, Margaret A. ;
Bradner, James E. .
CANCER CELL, 2013, 24 (06) :777-790
[9]   Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia [J].
Dawson, Mark A. ;
Prinjha, Rab K. ;
Dittmann, Antje ;
Giotopoulos, George ;
Bantscheff, Marcus ;
Chan, Wai-In ;
Robson, Samuel C. ;
Chung, Chun-wa ;
Hopf, Carsten ;
Savitski, Mikhail M. ;
Huthmacher, Carola ;
Gudgin, Emma ;
Lugo, Dave ;
Beinke, Soren ;
Chapman, Trevor D. ;
Roberts, Emma J. ;
Soden, Peter E. ;
Auger, Kurt R. ;
Mirguet, Olivier ;
Doehner, Konstanze ;
Delwel, Ruud ;
Burnett, Alan K. ;
Jeffrey, Phillip ;
Drewes, Gerard ;
Lee, Kevin ;
Huntly, Brian J. P. ;
Kouzarides, Tony .
NATURE, 2011, 478 (7370) :529-533
[10]   BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc [J].
Delmore, Jake E. ;
Issa, Ghayas C. ;
Lemieux, Madeleine E. ;
Rahl, Peter B. ;
Shi, Junwei ;
Jacobs, Hannah M. ;
Kastritis, Efstathios ;
Gilpatrick, Timothy ;
Paranal, Ronald M. ;
Qi, Jun ;
Chesi, Marta ;
Schinzel, Anna C. ;
McKeown, Michael R. ;
Heffernan, Timothy P. ;
Vakoc, Christopher R. ;
Bergsagel, P. Leif ;
Ghobrial, Irene M. ;
Richardson, Paul G. ;
Young, Richard A. ;
Hahn, William C. ;
Anderson, Kenneth C. ;
Kung, Andrew L. ;
Bradner, James E. ;
Mitsiades, Constantine S. .
CELL, 2011, 146 (06) :903-916